Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

jessica

August 3, 2021

Immunic, Inc. to Participate in Investor Conferences in August

NEW YORK, August 3, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
July 19, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

NEW YORK, July 19, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a...

Read More
July 15, 2021

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

NEW YORK, July 15, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a...

Read More
July 14, 2021

Immunic, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, July 14, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a...

Read More
June 28, 2021

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

NEW YORK, June 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 10, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in June

NEW YORK, June 10, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 1, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

NEW YORK, June 1, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
February 17, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including...

Read More
February 11, 2021

Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
January 5, 2021

Immunic, Inc. to Participate in Investor Conferences in January

– Management Provides Update on Timing of Data for IMU-838 in Primary...

Read More
December 14, 2020

Immunic, Inc. Added to NASDAQ Biotechnology Index

NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
December 2, 2020

BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Sichere...

Read More
November 24, 2020

Immunic, Inc. to Participate in Investor Conferences in December

NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
November 17, 2020

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E....

Read More